—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Arrowhead Pharmaceuticals Inc (ARWR) — Technical state

As of 2026-10-30 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 45 out of 100 (momentum 25 · quality 35 · valuation 13), as of 2026-11-01.
  • Signal: Downtrend stack — Trades -14.2% vs the 50-day and -16.5% vs the 200-day average, 37.3% below the 52-week high and +61.6% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes. (as of 2026-10-30)
  • Trend: Arrowhead Pharmaceuticals Inc trades 14.2% below its 50-day and 16.5% below its 200-day moving average. (as of 2026-10-30)

Arrowhead Pharmaceuticals develops RNA interference medicines aimed at chronic diseases, using its own delivery technology to silence disease-causing genes in the liver and other tissues. Its pipeline covers candidates for lipid disorders, kidney disease and other conditions, several partnered with larger drugmakers such as Takeda, Amgen and GlaxoSmithKline.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the ARWR overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Downtrend stack

Trades -14.2% vs the 50-day and -16.5% vs the 200-day average, 37.3% below the 52-week high and +61.6% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes.

The moving-average stack

Continue: the ARWR chart & overview · quality & forensics · the earnings record · the signal board

FAQ · from the current data · as of 2026-10-30

Quick answers

What is the current Closelooknet signal on ARWR?

Downtrend stack — Trades -14.2% vs the 50-day and -16.5% vs the 200-day average, 37.3% below the 52-week high and +61.6% off the 52-week low; a death cross printed 4 sessions ago. Computed from daily closes. As of 2026-10-30; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is ARWR above its 50-day and 200-day moving averages?

As of 2026-10-30, Arrowhead Pharmaceuticals Inc trades -14.2% below its 50-day and -16.5% below its 200-day average, with the 20-day +0.6% away.

How far is ARWR from its 52-week high?

37.3% below the 52-week high and 61.6% above the 52-week low, as of 2026-10-30.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.